Company Overview
Tango Therapeutics is a biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer.
Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer.
This includes expanding the universe of precision oncology targets into novel areas such as tumor suppressor gene loss and their contribution to the ability of cancer cells to evade immune cell killing.
The Tango labs and offices are located at 201 Brookline Avenue, in the Fenway area of Boston, Massachusetts.
Summary:
We are seeking a highly skilled, motivated attorney to join our team as Executive Director, Commercial Law/Commercial Contracts. Reporting to the SVP, General Counsel, this role will lead the commercial legal function and serve as a strategic partner to Tango’s growing Medical Affairs, Commercial, Patient Support, Market Access & Reimbursement functions as the Company advances toward its first commercial launch. This role will be responsible for providing hands-on, day-to-day legal advice on a wide range of strategic initiatives, including pre-launch activities, market access activities, patient support programs, and materials review (advertising/promotion and medical/scientific communications) and will lead the negotiation of commercial contracts.
The ideal candidate will bring excellent judgment, executive presence, broad-based expertise, and practical business orientation. This leader will be both a strategic advisor and a hands-on matter owner, able to build scalable processes, partner effectively across the enterprise, and translate complex legal risk into clear, actionable guidance for business leaders and the Executive Leadership Team.
Responsibilities:
- Provide pragmatic and solutions-oriented legal advice to the company’s rapidly growing commercial and medical affairs organizations
- Identify and resolve critical legal and business issues associated with pre-launch activities and launch strategy, including medical (e.g., MSL activities and programs), disease awareness, sales, marketing (brand messaging, activities and campaigns), patient advocacy programs, advisory boards, and other business activities
- Serve as a subject matter expert on U.S. healthcare laws, FDA promotional regulations and industry codes to enable legal and compliant pre-launch, launch and ongoing commercial and medical activities
- With the support of outside counsel as needed, lead the negotiation of business agreements in support of Tango’s anticipated product launches, including those with vendors, healthcare professionals, specialty pharmacies, patient support vendors, payor agreements, and distributors
- Provide ongoing contracting support and lifecycle management, including agreement interpretation and risk analysis, for Tango’s commercial, medical affairs, patient support, and other teams
- As a member of the Legal and Compliance Team, actively contribute to the function by building a positive culture, fostering engagement, sharing best practices and participating in initiatives focused on building departmental and functional knowledge and competencies
Education & Experience
- J.D. from an accredited law school and admitted to practice in at least one U.S. jurisdiction
- A minimum of 10-12 years of commercial law experience at a top-tier law firm and/or in a biotech company’s legal department
- In-house experience at a pharmaceutical/biotech company strongly preferred, experience supporting a company through its first launch ideal
- Ability to interpret legal requirements and deliver pragmatic, business-oriented guidance
- Deep knowledge of FDA promotional regulations, Anti-Kickback Statute, False Claims Act, OIG guidance, and industry codes, and ability to stay current on evolving trends and enforcement priorities
- Experience reviewing promotional and medical materials as a Legal reviewer
- Strong business partnering orientation with ability to balance risk and business goals
- Proven capability to manage multiple priorities and collaborative effectively in a fast-paced, collaborative environment; flexible and able to adapt to new situations as the business requires
- Excellent written and verbal communication skills
We are an equal opportunity employer and value diversity at our company.
We do not discriminate on the basis of race, religion, color, national origin, gender, sexual orientation, age, marital status, veteran status, or disability status.
Skills Required
- J.D. from an accredited law school
- Admission to practice in at least one U.S. jurisdiction
- 10–12 years of commercial law experience at a top-tier law firm and/or in a biotech legal department
- In-house experience at a pharmaceutical or biotechnology company
- Experience supporting a company through its first commercial launch
- Ability to interpret legal requirements and provide pragmatic, business-oriented guidance
- Deep knowledge of FDA promotional regulations, Anti-Kickback Statute, False Claims Act, OIG guidance, and industry codes
- Experience reviewing promotional and medical materials as a legal reviewer
- Strong business partnering skills and ability to balance risk with business goals
- Ability to manage multiple priorities and collaborate effectively in a fast-paced environment
- Excellent written and verbal communication skills
What We Do
Tango Therapeutics is a biotechnology company discovering and developing novel medicines targeting cancer vulnerabilities to deliver transformational new therapies for patients. Tango was launched in 2017 with a $55 million Series A investment from Third Rock Ventures. The company has established a robust product engine that leverages advances in DNA sequencing and CRISPR-based target discovery to generate breakthrough medicines that have the potential to provide deeper, more sustained benefit than today’s targeted therapies, and extend the benefit of available immuno-oncology agents. Tango Therapeutics is focused on three areas of drug development, each in well-defined patient populations currently lacking effective treatment options, and each with hallmarks of cancer that have not been targeted yet. These include: loss of tumor suppressor gene function; multiple oncogenic drivers; and immune evasion. What fuels each of Tango’s programs is an increasingly sophisticated ability to utilize synthetic lethality - the interaction between two genes that causes cell death when both are inactivated. In cancer cells, one of these genes is inactivated by mutation; the other will be inactivated by a drug. This approach leaves normal cells largely unaffected, with the potential to greatly enhance anti-tumor efficacy and reduce associated toxicity. Tango’s success will be driven by its depth of understanding of the genetic subtypes of cancer, and corresponding insights into novel drug targets and combinations uniquely relevant to each subtype. By shaping discovery efforts in this way, Tango has the potential to reach the clinic quickly, and with a clear plan for identifying the patients most likely to benefit from each new treatment, an approach that could increase both speed and probability of success in translating novel target discoveries into transformational new medicines for patients.
